REVLIMID® (lenalidomide) in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).
REVLIMID is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).
REVLIMID is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
REVLIMID is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
What you need to know about the REVLIMID REMS® program
Your doctor will enroll you in the REVLIMID REMS® program so that you can receive your medication. Use the materials below to learn more about the REVLIMID REMS® program, and what you need to do.
You can take your mandatory confidential patient survey at CelgeneRiskManagement.com in English or Spanish by clicking one of the buttons below.
Attention Females Who Can Get Pregnant
Unless you abstain from sexual intercourse with a male partner, you are required to use at the same time at least 1 highly effective birth control method and at least 1 additional effective method every time you have sex with a male. Below, you will find a printable letter that you can bring with you to your next medical appointment that discusses your reproductive health. This will help you and your healthcare provider understand what types of birth control options are best for you.
For additional information about the REVLIMID REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436
REVLIMID® and REVLIMID REMS® are registered trademarks of Celgene Corporation.
© 2013-2017. Celgene Corporation, www.celgene.com.
This website is intended for residents of the United States only.